SLRX logo

Salarius Pharmaceuticals (SLRX) Cash From Operations

Annual CFO

-$12.85 M
+$4.75 M+26.99%

December 31, 2023

Summary

Performance

1-Year Change

+26.99%

3-Year Change

-24.58%

5-Year Change

+45.56%

15-Year Change

+53.66%

SLRX Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

55.9%
SLRX annual cash flow from operations is higher than 55.9% of companies in Healthcare sector

High & Low

All-time High

-$10.20 M

3-Year Low

-$17.60 M

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
SLRX previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

Feb 28, 2025
SLRX next annual earnings announcement is scheduled for Feb 28, 2025

OtherSLRXcash flowmetrics:

Annual CFI

$0.00
SLRX annual cash flow from investing activities is $0.00

Annual CFF

$6.64 M
SLRX annual cash flow from financing activities is $6.64 million

Annual FCF

-$12.85 M
SLRX annual free cash flow is -$12.85 million

Annual CAPEX

-
SLRX annual capital expenditures value is unknown

Quarterly CFO

-$1.36 M
-$284.50 K-26.53%

September 30, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

0%

3-Year Change

+69.28%

5-Year Change

+69.28%

SLRX Quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

65.76%
SLRX quarterly cash flow from operations is higher than 65.76% of companies in Healthcare sector

High & Low

All-time High

-$743.00 K

3-Year Low

-$5.74 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
SLRX previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Feb 28, 2025
SLRX next earnings announcement is scheduled for Feb 28, 2025

OtherSLRXcash flowmetrics:

Quarterly CFI

-
SLRX quarterly cash flow from investing activities value is unknown

Quarterly CFF

$1.37 M
SLRX quarterly cash flow from financing activities is $1.37 million

Quarterly FCF

-$1.36 M
SLRX quarterly free cash flow is -$1.36 million

Quarterly CAPEX

-
SLRX quarterly capital expenditures value is unknown

TTM CFO

-$5.29 M
+$2.39 M+31.12%

September 30, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

0%

3-Year Change

+70.65%

5-Year Change

+70.65%

SLRX TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

67.61%
SLRX TTM cash flow from operations is higher than 67.61% of companies in Healthcare sector

High & Low

All-time High

-$4.14 M

3-Year Low

-$18.04 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
SLRX previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Feb 28, 2025
SLRX next earnings announcement is scheduled for Feb 28, 2025

OtherSLRXcash flowmetrics:

TTM CFI

-
SLRX TTM cash flow from investing activities value is unknown

TTM CFF

$997.60 K
SLRX TTM cash flow from financing activities is $997.60 thousand

TTM FCF

-$5.29 M
SLRX TTM free cash flow is -$5.29 million

TTM CAPEX

-
SLRX TTM capital expenditures value is unknown

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

SLRX Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+27.0%0.0%0.0%
3 y3 years-24.6%+69.3%+70.7%
5 y5 years+45.6%+69.3%+70.7%

SLRX Cash From Operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-25.9%+27.0%-26.5%+76.4%at high+70.7%
5 y5-year-25.9%+27.0%-26.5%+76.4%at high+70.7%
alltimeall time-25.9%+59.9%-82.6%+85.6%-27.9%+83.5%

Salarius Pharmaceuticals Cash From Operations History

DateAnnualQuarterlyTTM
Sep 2024
-
-$1.36 M(+26.5%)
-$5.29 M(-31.1%)
Jun 2024
-
-$1.07 M(-20.8%)
-$7.69 M(-30.3%)
Mar 2024
-
-$1.35 M(-10.4%)
-$11.03 M(-14.1%)
Dec 2023
-$12.85 M(-27.0%)
-$1.51 M(-59.7%)
-$12.85 M(-20.0%)
Sep 2023
-
-$3.75 M(-15.1%)
-$16.05 M(-11.0%)
Jun 2023
-
-$4.42 M(+39.3%)
-$18.04 M(+4.6%)
Mar 2023
-
-$3.17 M(-32.8%)
-$17.24 M(-2.0%)
Dec 2022
-$17.60 M(+72.5%)
-$4.71 M(-17.9%)
-$17.60 M(+12.8%)
Sep 2022
-
-$5.74 M(+58.6%)
-$15.60 M(+36.3%)
Jun 2022
-
-$3.62 M(+2.8%)
-$11.44 M(+4.0%)
Mar 2022
-
-$3.52 M(+29.4%)
-$11.00 M(+7.8%)
Dec 2021
-$10.20 M(-1.1%)
-$2.72 M(+72.0%)
-$10.20 M(+15.2%)
Sep 2021
-
-$1.58 M(-50.2%)
-$8.85 M(-11.7%)
Jun 2021
-
-$3.17 M(+16.6%)
-$10.02 M(+7.5%)
Mar 2021
-
-$2.72 M(+98.2%)
-$9.33 M(-9.6%)
Dec 2020
-$10.31 M(-11.0%)
-$1.37 M(-50.1%)
-$10.31 M(-10.9%)
Sep 2020
-
-$2.75 M(+11.2%)
-$11.57 M(-19.4%)
Jun 2020
-
-$2.48 M(-33.2%)
-$14.36 M(+13.7%)
Mar 2020
-
-$3.71 M(+40.6%)
-$12.63 M(+9.1%)
DateAnnualQuarterlyTTM
Dec 2019
-$11.58 M(-50.9%)
-$2.64 M(-52.4%)
-$11.58 M(-4.1%)
Sep 2019
-
-$5.54 M(+645.9%)
-$12.08 M(+29.4%)
Jun 2019
-
-$743.00 K(-72.1%)
-$9.33 M(-44.6%)
Mar 2019
-
-$2.66 M(-15.2%)
-$16.84 M(-28.6%)
Dec 2018
-$23.60 M(-14.9%)
-$3.13 M(+12.1%)
-$23.60 M(-10.0%)
Sep 2018
-
-$2.80 M(-66.1%)
-$26.22 M(-16.7%)
Jun 2018
-
-$8.26 M(-12.3%)
-$31.47 M(+8.9%)
Mar 2018
-
-$9.41 M(+63.5%)
-$28.91 M(+4.3%)
Dec 2017
-$27.72 M(-13.5%)
-$5.76 M(-28.5%)
-$27.72 M(-1.9%)
Sep 2017
-
-$8.05 M(+41.5%)
-$28.27 M(+2.9%)
Jun 2017
-
-$5.69 M(-30.8%)
-$27.47 M(-11.7%)
Mar 2017
-
-$8.23 M(+30.6%)
-$31.10 M(-3.0%)
Dec 2016
-$32.05 M(+54.5%)
-$6.30 M(-13.1%)
-$32.05 M(+2.8%)
Sep 2016
-
-$7.25 M(-22.3%)
-$31.19 M(+1.8%)
Jun 2016
-
-$9.33 M(+1.7%)
-$30.64 M(+18.9%)
Mar 2016
-
-$9.17 M(+68.7%)
-$25.78 M(+24.3%)
Dec 2015
-$20.75 M
-$5.44 M(-18.9%)
-$20.75 M(+35.5%)
Sep 2015
-
-$6.70 M(+50.1%)
-$15.31 M(+77.9%)
Jun 2015
-
-$4.46 M(+7.8%)
-$8.61 M(+107.8%)
Mar 2015
-
-$4.14 M
-$4.14 M

FAQ

  • What is Salarius Pharmaceuticals annual cash flow from operations?
  • What is the all time high annual CFO for Salarius Pharmaceuticals?
  • What is Salarius Pharmaceuticals annual CFO year-on-year change?
  • What is Salarius Pharmaceuticals quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Salarius Pharmaceuticals?
  • What is Salarius Pharmaceuticals quarterly CFO year-on-year change?
  • What is Salarius Pharmaceuticals TTM cash flow from operations?
  • What is the all time high TTM CFO for Salarius Pharmaceuticals?
  • What is Salarius Pharmaceuticals TTM CFO year-on-year change?

What is Salarius Pharmaceuticals annual cash flow from operations?

The current annual CFO of SLRX is -$12.85 M

What is the all time high annual CFO for Salarius Pharmaceuticals?

Salarius Pharmaceuticals all-time high annual cash flow from operations is -$10.20 M

What is Salarius Pharmaceuticals annual CFO year-on-year change?

Over the past year, SLRX annual cash flow from operations has changed by +$4.75 M (+26.99%)

What is Salarius Pharmaceuticals quarterly cash flow from operations?

The current quarterly CFO of SLRX is -$1.36 M

What is the all time high quarterly CFO for Salarius Pharmaceuticals?

Salarius Pharmaceuticals all-time high quarterly cash flow from operations is -$743.00 K

What is Salarius Pharmaceuticals quarterly CFO year-on-year change?

Over the past year, SLRX quarterly cash flow from operations has changed by $0.00 (0.00%)

What is Salarius Pharmaceuticals TTM cash flow from operations?

The current TTM CFO of SLRX is -$5.29 M

What is the all time high TTM CFO for Salarius Pharmaceuticals?

Salarius Pharmaceuticals all-time high TTM cash flow from operations is -$4.14 M

What is Salarius Pharmaceuticals TTM CFO year-on-year change?

Over the past year, SLRX TTM cash flow from operations has changed by $0.00 (0.00%)